ProQR Therapeutics N.V. (PRQR) stock
PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.04−0.01 (-0.95%)
Close on Nov 20, 2026Market cap $109.58MP/E –Yield –
ProQR Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
ProQR Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -€50.16M. For fiscal 2025 it was -€53.81M. The highest annual figure on record is €20.18M in fiscal 2023.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€53.81M | – |
| FY2024 | Dec 31, 2024 | -€37.81M | -287.4% |
| FY2023 | Dec 31, 2023 | €20.18M | – |
| FY2022 | Dec 31, 2022 | -€69.22M | – |
| FY2021 | Dec 31, 2021 | -€26.50M | – |
| FY2020 | Dec 31, 2020 | -€47.98M | – |
| FY2019 | Dec 31, 2019 | -€44.55M | – |
| FY2018 | Dec 31, 2018 | -€28.81M | – |
| FY2017 | Dec 31, 2017 | -€35.07M | – |
| FY2016 | Dec 31, 2016 | -€36.76M | – |
| FY2015 | Dec 31, 2015 | -€25.53M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -€12.56M | – |
| Q1 FY2026 | Mar 31, 2026 | -€11.31M | – |
| Q4 FY2025 | Dec 31, 2025 | -€13.88M | – |
| Q3 FY2025 | Sep 30, 2025 | -€12.40M | – |
| Q2 FY2025 | Jun 30, 2025 | -€11.50M | – |
| Q1 FY2025 | Mar 31, 2025 | -€16.02M | – |
| Q4 FY2024 | Dec 31, 2024 | -€9.48M | – |
| Q3 FY2024 | Sep 30, 2024 | -€5.94M | – |
| Q2 FY2024 | Jun 30, 2024 | -€6.52M | – |
| Q1 FY2024 | Mar 31, 2024 | -€15.86M | -135.6% |
| Q4 FY2023 | Dec 31, 2023 | -€5.92M | – |
| Q3 FY2023 | Sep 30, 2023 | -€7.85M | – |
| Q2 FY2023 | Jun 30, 2023 | -€10.64M | – |
| Q1 FY2023 | Mar 31, 2023 | €44.59M | – |
| Q4 FY2022 | Dec 31, 2022 | -€17.82M | -600.6% |
| Q3 FY2022 | Sep 30, 2022 | -€15.61M | – |
| Q2 FY2022 | Jun 30, 2022 | -€15.08M | – |
| Q1 FY2022 | Mar 31, 2022 | -€20.71M | – |
| Q4 FY2021 | Dec 31, 2021 | €3.56M | – |
| Q3 FY2021 | Sep 30, 2021 | -€8.23M | – |
| Q2 FY2021 | Jun 30, 2021 | -€10.03M | – |
| Q1 FY2021 | Mar 31, 2021 | -€11.79M | – |
| Q4 FY2020 | Dec 31, 2020 | -€11.87M | – |
| Q3 FY2020 | Sep 30, 2020 | -€10.07M | – |
| Q2 FY2020 | Jun 30, 2020 | -€10.83M | – |
| Q1 FY2020 | Mar 31, 2020 | -€15.21M | – |
| Q4 FY2019 | Dec 31, 2019 | -€12.20M | – |
| Q3 FY2019 | Sep 30, 2019 | -€8.80M | – |
| Q2 FY2019 | Jun 30, 2019 | -€10.96M | – |
| Q1 FY2019 | Mar 31, 2019 | -€12.59M | – |
| Q4 FY2018 | Dec 31, 2018 | -€9.13M | – |
| Q3 FY2018 | Sep 30, 2018 | -€4.36M | – |
| Q2 FY2018 | Jun 30, 2018 | -€5.61M | – |
| Q2 FY2017 | Jun 30, 2017 | -€9.89M | – |
See a number that looks wrong?